
Call for Editorial Board Members

As you are well aware that we are a medical and health sciences publishers; publishing peer-reviewed journals and books since 2004.

We are always looking for dedicated editorial board members for our journals. If you completed your master degree and must have at least five years experience in teaching and having good publication records in journals and books.

If you are interested to be an editorial board member of the journal; please provide your complete resume and affiliation through e-mail (i.e. info@rfppl.co.in) or visit our website (i.e. www.rfppl.co.in) to register yourself online.

Call for Publication of Conference Papers/Abstracts

We publish pre-conference or post-conference papers and abstracts in our journals, and deliver hard copy and giving online access in a timely fashion to the authors.

For more information, please contact:

For more information, please contact:
A Lal
Publication-in-charge
Red Flower Publication Pvt. Ltd.
48/41-42, DSIDC, Pocket-II
Mayur Vihar Phase-I
Delhi - 110 091 (India)
Phone: 91-11-79695648
E-mail: info@rfppl.co.in

Call for Editorial Board Members

As you are well aware that we are a medical and health sciences publishers; publishing peer-reviewed journals and books since 2004.

We are always looking for dedicated editorial board members for our journals. If you completed your master degree and must have at least five years experience in teaching and having good publication records in journals and books.

If you are interested to be an editorial board member of the journal; please provide your complete resume and affiliation through e-mail (i.e. info@rfppl.co.in) or visit our website (i.e. www.rfppl.co.in) to register yourself online.

Call for Publication of Conference Papers/Abstracts

We publish pre-conference or post-conference papers and abstracts in our journals, and deliver hard copy and giving online access in a timely fashion to the authors.

For more information, please contact:

For more information, please contact:

A Lal

Publication-in-charge

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091 (India)

Phone: 91-11-79695648

E-mail: info@rfppl.co.in

Win Free Institutional Subscription!

Simply fill out this form and return scanned copy through e-mail or by post to us.

Name of the Institution_____

Name of the Principal/Chairman_____

Management (Trust/Society/Govt./Company)_____

Address 1_____

Address 2_____

Address 3_____

City_____

Country_____

PIN Code_____

Mobile_____

Email_____

We are regular subscriber of Red Flower Publication journals.

Year of first subscription_____

List of ordered journals (if you subscribed more than 5 titles, please attach separate sheet)

Ordered through

Name of the Vendor	Subscription Year	Direct/subs Yr

Name of the journal for which you wish to be free winner

Terms & Conditions to win free institutional subscription

1. Only institutions can participate in this scheme
2. In group institutions only one institution would be winner
3. Only five institutions will be winner for each journal
4. An institution will be winner only for one journal
5. The free subscription will be valid for one year only (i.e. 1, Jan - 31, Dec)
6. This free subscription is not renewable, however can be renewed with payment
7. Any institution can again participate after five years
8. All legal disputes subject to Delhi jurisdiction only
9. This scheme will be available to participate throughout year, but draw will be held in last week of August every year
10. The executive committee of the Red Flower Publication reserve the right to cancel, revise or modify terms and conditions any time without notice.

I confirm and certify that the above information is true and correct to the best of my knowledge and belief.

Place:

Signature with Seal

Date:

<i>Revised Rates for 2023 (Institutional)</i>					
Title of the Journal	Frequency	India(INR) Print Only	India(INR) Online Only	Outside India(USD) Print Only	Outside India(USD) Online Only
Community and Public Health Nursing	Triannual	6500	6000	507.81	468.75
Indian Journal of Agriculture Business	Semiannual	6500	6000	507.81	468.75
Indian Journal of Anatomy	Quarterly	9500	9000	742.19	703.13
Indian Journal of Ancient Medicine and Yoga	Quarterly	9000	8500	703.13	664.06
Indian Journal of Anesthesia and Analgesia	Bi-monthly	8500	8000	664.06	625
Indian Journal of Biology	Semiannual	6500	6000	507.81	468.75
Indian Journal of Cancer Education and Research	Semiannual	10000	9500	781.25	742.19
Indian Journal of Communicable Diseases	Semiannual	9500	9000	742.19	703.13
Indian Journal of Dental Education	Quarterly	6500	6000	507.81	468.75
Indian Journal of Diabetes and Endocrinology	Semiannual	9000	8500	703.13	664.06
Indian Journal of Emergency Medicine	Quarterly	13500	13000	1054.69	1015.63
Indian Journal of Forensic Medicine and Pathology	Quarterly	17000	16500	1328.13	1289.06
Indian Journal of Forensic Odontology	Semiannual	6500	6000	507.81	468.75
Indian Journal of Genetics and Molecular Research	Semiannual	8000	7500	625	585.94
Indian Journal of Law and Human Behavior	Semiannual	7000	6500	546.88	507.81
Indian Journal of Legal Medicine	Semiannual	9500	9000	742.19	703.13
Indian Journal of Library and Information Science	Triannual	10500	10000	820.31	781.25
Indian Journal of Maternal-Fetal & Neonatal Medicine	Semiannual	10500	10000	820.31	781.25
Indian Journal of Medical and Health Sciences	Semiannual	8000	7500	625	585.94
Indian Journal of Obstetrics and Gynecology	Quarterly	10500	10000	820.31	781.25
Indian Journal of Pathology: Research and Practice	Triannual	13000	12500	1015.63	976.56
Indian Journal of Plant and Soil	Semiannual	7500	7000	585.94	546.88
Indian Journal of Preventive Medicine	Semiannual	8000	7500	625	585.94
Indian Journal of Research in Anthropology	Semiannual	13500	13000	1054.69	1015.63
Indian Journal of Surgical Nursing	Triannual	6500	6000	507.81	468.75
Indian Journal of Trauma and Emergency Pediatrics	Quarterly	10500	10000	820.31	781.25
Indian Journal of Waste Management	Semiannual	10500	10000	820.31	781.25
International Journal of Food, Nutrition & Dietetics	Triannual	6500	6000	507.81	468.75
International Journal of Forensic Science	Semiannual	11000	10500	859.38	820.31
International Journal of Neurology and Neurosurgery	Quarterly	11500	11000	898.44	859.68
International Journal of Pediatric Nursing	Triannual	6500	6000	507.81	468.75
International Journal of Political Science	Semiannual	7000	6500	546.88	507.81
International Journal of Practical Nursing	Triannual	6500	6000	507.81	468.75
International Physiology	Triannual	8500	8000	664.06	625
Journal of Aeronautical Dentistry	Quarterly	8000	7500	625	585.94
Journal of Animal Feed Science and Technology	Semiannual	9000	8500	703.13	664.06
Journal of Cardiovascular Medicine and Surgery	Quarterly	11000	10500	859.38	820.31
Journal of Emergency and Trauma Nursing	Semiannual	6500	6000	507.81	468.75
Journal of Food Additives and Contaminants	Semiannual	6500	6000	507.81	468.75
Journal of Food Technology and Engineering	Semiannual	6000	5500	468.75	429.69
Journal of Forensic Chemistry and Toxicology	Semiannual	10500	10000	820.31	781.25
Journal of Global Medical Education and Research	Semiannual	7000	6500	546.88	507.81
Journal of Global Public Health	Semiannual	13000	12500	1015.63	976.56
Journal of Microbiology and Related Research	Semiannual	9500	9000	742.19	703.13
Journal of Nurse Midwifery and Maternal Health	Triannual	6500	6000	507.81	468.75
Journal of Orthopedic Education	Triannual	6500	6000	507.81	468.75
Journal of Pharmaceutical and Medicinal Chemistry	Semiannual	17500	17000	1367.19	1328.13
Journal of Plastic Surgery and Transplantation	Semiannual	27500	27000	2148.44	2109.38
Journal of Psychiatric Nursing	Triannual	6500	6000	507.81	468.75
Journal of Radiology	Semiannual	9000	8500	703.13	664.06
Journal of Social Welfare and Management	Quarterly	8500	8000	664.06	625
New Indian Journal of Surgery	Quarterly	9000	8500	703.13	664.06
Ophthalmology and Allied Sciences	Triannual	7000	6500	546.88	507.81
Pediatrics Education and Research	Quarterly	8500	8000	664.06	625
Physiotherapy and Occupational Therapy Journal	Quarterly	10000	9500	781.25	742.19
RFP Gastroenterology International	Semiannual	7000	6500	546.88	507.81
RFP Indian Journal of Hospital Infection	Semiannual	13500	13000	1054.69	1015.63
RFP Indian Journal of Medical Psychiatry	Semiannual	9000	8500	703.13	664.06
RFP Journal of Biochemistry and Biophysics	Semiannual	8000	7500	625	585.94
RFP Journal of Dermatology	Semiannual	6500	6000	507.81	468.75
RFP Journal of ENT and Allied Sciences	Semiannual	6500	6000	507.81	468.75
RFP Journal of Gerontology and Geriatric Nursing	Semiannual	6500	6000	507.81	468.75
RFP Journal of Hospital Administration	Semiannual	8000	7500	625	585.94
Urology, Nephrology and Andrology International	Semiannual	8500	8000	664.06	625
Terms of Supply: <ol style="list-style-type: none"> Agency discount 12.5%. Issues will be sent directly to the end user, otherwise foreign rates will be charged. All back volumes of all journals are available at current rates. All journals are available free online with print order within the subscription period. All legal disputes subject to Delhi jurisdiction. Cancellations are not accepted orders once processed. Demand draft/cheque should be issued in favour of “Red Flower Publication Pvt. Ltd.” payable at Delhi. Full pre-payment is required. It can be done through online (http://rfppl.co.in/subscribe.php?mid=7). No claims will be entertained if not reported within 6 months of the publishing date. Orders and payments are to be sent to our office address as given below. Postage & Handling is included in the subscription rates. Subscription period is accepted on calendar year basis (i.e. Jan to Dec). However orders may be placed any time throughout the year. 					
Order from Red Flower Publication Pvt. Ltd., 48/41-42, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi - 110 091 (India) Mobile: 8130750089, Phone: 91-11-79695648 E-mail: sales@rfppl.co.in , Website: www.rfppl.co.in					

RFP Indian Journal of Hospital Infection

Editor-in-Chief

Ramendra Pati Pandey

University of Sao Paulo School of Medicine Sao Paulo, Brazil.

National Editorial Board Member

Sayan Bhattacharyya,

Kolkata, Associate Professor, Microbiology, All India Institute of Hygiene and Public Health, Kolkata, West Bengal 700098, India., West Bengal, India.

E-mail: sayantheboss@yahoo.co.in

Mosin Saleem Khan,

Senior Resident,

Department of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Kashmir 190011, India.

E-mail: mosinskims@gmail.com

Syed Mudassar Andrabi,

Professor & Head,

Department of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Kashmir 190011, India.

E-mail: syed.mudassar@skims.ac.in

Deo Mani Tripathi,

Associate Professor & Former Coordinator,

Department of Medical Lab Technology,

Post Graduate Department of Zoology,

Govt. Autonomous Post Graduate College, Rishikesh, Dehradun, Uttarakhand 249201, India.

E-mail: dmtripathi31@gmail.com

Pascaline V.R. Martis,

Associate Professor,

V.S.P.M's College of Nursing and Research Centre, Nagpur, Maharashtra 440019, India.

E-mail: pascalinemartis@gmail.com

Kumkum Sarkar,

Assistant Professor,

Department of Tropical Medicine, School of Tropical Medicine, Kolkata, West Bengal 700073, India.

E-mail: dr.kumkum.sarkar@gmail.com

Rahul D. Suryawanshi

Udgir, Maharashtra, India

Indian Veterinary Research Institute (IVRI), Bareilly, UP

E-mail: rahulvph@gmail.com

Managing Editor

A. Lal

Publication Editor

Dinesh Kumar Kashyap

All right reserved. The views and opinions expressed are of the authors and not of the **RFP Indian Journal of Hospital Infection**. The **RFP Indian Journal of Hospital Infection** does not guarantee directly or indirectly the quality or efficacy of any product or service featured in the advertisement in the journal, which are purely commercial.

Corresponding address

Red Flower Publication Pvt. Ltd. 48/41-42 DSIDC, Pocket II, Mayur Vihar Phase I, Delhi 110 091 (India)
Phone: 91-11-79695648, Email: info@rfppl.co.in, Web: www.rfppl.co.in

RFP Indian Journal of Hospital Infection publishes scientifically authoritative, clinically applicable, peer-reviewed research on control and evaluation of the transmission of pathogens in healthcare institutions and on the use of epidemiological principles and methods to evaluate and improve the delivery of care. Major topics covered include infection control practices, surveillance, cost benefit analyses, resource use, occupational health, and regulatory issues. IJHI is the foremost resource on infection control, epidemiology, infectious diseases, quality management, occupational health, and disease prevention. The aim of the Journal is to publish high quality research and information relating to infection prevention and control that is relevant to an international audience.

Subscription Order Information

Annual Rate (Institutional): India INR 13000/Other Countries USD 1016

Wire transfer:

Complete Bank Account No. 604320110000467
Beneficiary Name: Red Flower Publication Pvt. Ltd.
Bank & Branch Name: Bank of India; Mayur Vihar
MICR Code: 110013045
Branch Code: 6043
IFSC Code: BKID0006043 (used for RTGS and NEFT transactions)
Swift Code: BKIDINBBDOS

Cheque:

Please send the US dollar check from outside India and INR check from India made:
Payable to 'Red Flower Publication Private Limited'.
Drawn on Delhi branch

PayPal Instructions for the payment (only for transfer from outside India):

Payments can be made through our PayPal account at <https://www.paypal.com>. Our PayPal recipient email address is redflowerppl@gmail.com.

PayUmoney Instructions for the payment (only for transfer within India):

Payments can be made through our PayUmoney account at <https://www.payumoney.com/buyer.html>. Our PaUmoney receipt detail is:

Account name: Red Flower Publication Private Limited
Bank Name: Bank of India
A/c No.604320110000467
IFSC Code: BKID0006043
Branch: Mayur Vihar

Bank Address: Do not send cheque or order to this address

13/14, Sri Balaji Shop, Pocket II
Mayur Vihar Phase I
Delhi – 110 091 (India)

Credit Card:

We accept Visa or MasterCard.

*Please kindly add bank charge at your side if you pay by check or wire transfer.

Please forward all payments, orders and all other order related letters to;

Red Flower Publication Pvt. Ltd.
48/41-42, DSIDC, Pocket II
Mayur Vihar Phase I
Delhi 110 091 (India)

Send all Orders to: **Red Flower Publication Pvt. Ltd.**, 48/41-42, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi – 110091 (India). Phone: 011-79695648, E-mail: info@rfppl.co.in, Website: www.rfppl.co.in

RFP Indian Journal of Hospital Infection

Volume 5 Number 1
January - June 2023

Contents

Original Articles

- Biomedical Waste Management: Pre and Post Covid-19 Pandemic** 9
Kavitha M.G., Ramachandra Rao S, Visanth.V.S

Review Articles

- Antimicrobial Resistance and Antimicrobial Stewardship** 19
Sayan Bhattacharyya

Short Communication

- A Study of Malaria in National Capital Territory of Delhi** 25
Arvind Nath
- Guidelines for Authors** 31

Red Flower Publication (P) Ltd.
Presents its Book Publications for sale

1. Beyond Medicine: A to E for Medical Professionals) (2020)
Kalidas Chavan
INR390/USD31
2. Biostatistical Methods For Medical Research (2019)
Sanjeev Sarmukaddam
3. Breast Cancer: Biology, Prevention And Treatment (2015)
Dr. A. Ramesh Rao
4. Chhotanagpur A Hinterland of Tribes (2020)
Ambrish Gautam
5. Child Intelligence (2004)
Dr. Rajesh Shukla, Md, Dch.
6. Clinical Applied Physiology and Solutions (2020)
Varun Malhotra
7. Comprehensive Medical Pharmacology (2019)
Dr. Ahmad Najmi
8. Critical Care Nursing in Emergency Toxicology (2019)
Vivekanshu Verma
9. Digital Payment (Blue Print For Shining India) (2020)
Dr. Bishnu Prasad Patro
10. Drugs in Anesthesia (2020)
R. Varaprasad
11. Drugs In Anesthesia and Critical Care (2020)
Dr. Bhavna Gupta
12. MCQs in Medical Physiology (2019)
Dr. Bharati Mehta
13. MCQs in Microbiology, Biotechnology and Genetics (2020)
Biswajit Batabyal
14. MCQs In Minimal Access and Bariatric Surgery (2nd Edition) (2020)
Anshuman Kaushal
15. Patient Care Management (2019)
A.K. Mohiuddin
16. Pediatrics Companion (2001)
Rajesh Shukla
17. Pharmacuetics-1 (A Comprehensive Hand Book) (2021)
V. Sandhiya
18. Poultry Eggs of India (2020)
Prafulla K. Mohanty
19. Practical Emergency Trauma Toxicology Cases Workbook (2019)
Dr. Vivekanshu Verma, Dr. Shit Rattan Kochar, Dr. Devendra Richhariya
20. Practical Record Book of Forensic Medicine & Toxicology (2019)
Dr. Akhilesh K. Pathak

21. Recent Advances in Neonatology (2020)
Dr. T.M. Ananda Kesavan
INR 845/USD66
22. Shipping Economics (2018)
Dr. D. Amutha
INR347/USD45
23. Skeletal and Structural Organizations of Human Body (2019)
Dr. D.R. Singh
INR659/USD51
24. Statistics In Genetic Data Analysis (2020)
S.Venkatasubramanian
INR299/USD23
25. Synopsis of Anesthesia (2019)
Dr. Lalit Gupta
INR1195/USD75
26. A Handbook of Outline of Plastic Surgery Exit Examination (2022)
Prof Ravi Kumar Chittoria & Dr. Saurabh Gupta
INR 498/USD 38
27. An Introductory Approach to Human Physiology (2021)
Satyajit Tripathy, Barsha Dassarma, Motlalpula Gilbert Matsabisa
INR 599/USD 46
28. Biochemical and Pharmacological Variations in Venomous Secretion of Toad (*Bufo melanostictus*)(2021)
Dr. Thirupathi Koila & Dr. Venkaidh Yanamala
INR 325/USD26
29. Climate, Prey & Predator Insect Poupulation in Bt Cotton and Non-Bt Cotton Agriculture Feilds of Warangal District (2022)
Dr. Peesari Laxman,Ch. Sammalah
INR 325/USD26
30. Community Health Nursing Record Book Volume - I & II (2022)
Ritika Rocque
INR 999/USD 79
31. Handbook of Forest Terminologies (Volume I & II) (2022)
Dr. C.N.Hari Prasath, Dr. A. Balasubramanian, Dr. M. Stooprakash, V. Maninanan, Dr. G. Swathiga
INR 1325/USD 104
32. MCQs of Biochemistry(2022)
Sachin C. Narwadiya, Dr. Irfana Begum
INR 399/USD 49
33. Newborn Care in the State of Uttar Pradesh(2022)
Dr. Tridibesh Tripathy
INR 545/USD 42
34. Osteoporosis: Weak Bone Disease(2022)
Dr. Dondeji Uday Kumar & Dr. R. B. Uppin
INR 399/USD49
35. Quick Updates in Anesthesia(2022)
Dr. Rupinder Kaur Kaiche, Dr. Vidhyadhar Modak, Dr. Shilpa Sannakki & Dr. Vivek Gupta
INR 599/USD 44
36. Textbook of Practice of Medicine with Homeopathic Therapeutics(2022)
Dr. Pramod Kumar
INR 1325/USD104
37. Trends in Anthropological Research(2022)
Dr. Jyoti Ratan Ghosh, Dr. Rangya Gachui
INR 399/USD 49

Order from: Red Flower Publication Pvt. Ltd., 48/41-42, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi - 110 091(India), Mobile: 8130750089, Phone: 91-11-79695648, E-mail: info@rfpl.co.in, Website: www.rfpl.co.in

Biomedical Waste Management: Pre and Post Covid-19 Pandemic

Kavitha M.G.¹, Ramachandra Rao S², Visanth. V.S³

How to cite this article:

Kavitha M.G., Ramachandra Rao S, Visanth.V.S/Biomedical Waste Management: Pre and Post Covid-19 Pandemic/
RFP Indian Journal of Hospital Infection, 2023,5(1):9-15.

Abstract

India is a developing nation with a vast health care network, effectively managing biological waste is a significant concern. The rising demand of health care services also gives light into effective biomedical waste. Because it has so many implications as a danger factor for both the health of patients, hospital employees, and extending beyond the confines of the medical institution to the general population, hospital waste generation has thus become a top issue. By doing effective management of biomedical waste management, we secure environment, as well as human health for current and future generation. India is one of the nation's most severely affected by the COVID 19 pandemic. The immediate change in the healthcare sector compels the government to update the current biomedical waste management regulations. This paper reviews the changes occur in the management of biomedical waste in India and amendments in the law in order to improve the public health & safety during the pandemic while handling biomedical waste.

Keywords: Biomedical waste rules; Covid-19; CPCB.

INTRODUCTION

Since 2016, the healthcare sector in India has been growing at a Compound Annual Growth Rate of over 22%. Hospitals, medical equipment,

health insurance, clinical trials, telemedicine, and medical tourism are all part of India's healthcare sector. In India, the hospital sector makes up 80% of the entire healthcare market.¹ The industry is going in a tremendous momentum. This rising demand of health care services also gives light into effective biomedical waste management. Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) exposure worries in the 1980s and 1990s raised concerns about potential risks associated with medical waste. Because it has so many implications as a danger factor for both the health of patients, hospital employees, and extending beyond the confines of the medical institution to the general population, hospital waste generation has thus become a top issue.² By doing effective management of biomedical waste management, we secure environment, as well as human health for current and future generation.³ Hospital cleanliness and infection control are impacted

Author Affiliation: ¹Postgraduate Student, School of Public Health, All India Institute of Medical Sciences, Jodhpur 342001, Rajasthan, India, ²Reader & Nodal Officer, Department of Reproductive Biomedicine, National Institute of Health and Family Welfare, New Delhi 110022, India, ³Assistant Nursing, Superintendent, Hospital Infection Control Committee, All India Institute of Medical Sciences, Patna 801507, Bihar, India.

Correspondence Author: Kavitha M.G., Postgraduate Student, School of Public Health, All India Institute of Medical Sciences, Jodhpur 342001, Rajasthan, India.

E-mail: kavitha.nair556@gmail.com

Received on: 05.04.2023

Accepted on: 19.04.2023

by how medical waste is managed. At the UN Sustainable Development Summit held in January 2015 in New York, the member states of the UN approved 17 Sustainable Development Goals that must be accomplished by them by the year 2030.⁴ Among these 17 goals, SDG 3 is "Good Health and Well Being," and crucial since it strives to offer everyone access to the highest caliber of healthcare. One of the biggest obstacles to providing humanity with the highest quality healthcare services is biomedical waste, which has become a major issue in recent years. Biomedical Waste has been defined as is "any waste, which is generated during the diagnosis, treatment or immunization of human beings or animals or research activities pertaining thereto or in the Production or testing of biological or in health camps."⁵ According to World Health Organization (WHO) 85% of the waste produced by the health care setting are non-hazardous and 15% are hazardous. The term "Health Care Waste" or "Biomedical Waste" includes all the wastes from any medical procedure in healthcare facilities, research centres and laboratories. The classification is based on presence of infectious substances, radioactivity, presence of sharps, genotoxic, cytotoxic, other toxic chemicals, and biologically aggressive pharmaceuticals.⁶

Hospital patients, healthcare staff, and the general public might become ill as a result of improper biological waste management handling and practices. A Report released by the World Health Organization (WHO, 2003) on the burden of diseases caused by needle stick injuries (NSIs) in healthcare workers, there were 3 million accidental injuries that resulted in 37% of new HBV infections, 39% of new HCV cases, and roughly 5.5% of new HIV cases.⁷ This will result in 9.2 million DALYs, or disability-adjusted life years between 2000 and 2030.⁸ Ultimately effective biomedical management will be able to reduce and manage these occupational dangers. A situational analysis study and performance predictors were done in 2014 by the International Clinical Epidemiology Network (INCLEN) Program Evaluation Network (IPEN) in 25 districts across 20 Indian states. According to the survey, 82% of primary care, 60% of secondary care, and 54% of tertiary care health facilities in the 25 study districts lack a reliable BMW management system or one that needs significant improvement.⁹

India is one of the nation's most severely affected by the COVID-19 pandemic.¹⁰ The GOI also implemented many preventive and precautionary measures as a result of the increasing infectivity rate. Health care settings are seeing a significant

demand for PPE from all strata of health care workers due to the fear of infection. Which led to a significant increase in the use of personal protective equipment.¹¹ The fear frequently leads to the overuse of PPE, which frequently intensifies the issue by producing many BMWs that are challenging to store and transport with the limited resources and manpower available during a crisis.¹² The actions taken to abolish single-use plastics quickly transitioned to a massive reliance on single-use plastics like PPEs for pandemic COVID 19 prevention and control.¹³ The immediate change in the healthcare sector compels the government to update the current biomedical waste management regulations. Since India is a developing nation with a vast health care network, effectively managing biological waste is a significant concern.

BMW DEVELOPMENTS IN INDIA

Under the Environmental Protection Act of 1986, the Government of India by Ministry of Environment and Forest published the first-Bio-Medical Waste (Management and Handling) Rules in 1998.¹⁴ Central Pollution Control Board (CPCB) the apex organization in country in the field of pollution control. It was established in 1974 under the Water (Prevention and Control of pollution) Act, 1974. By offering technical support and direction and mediating conflicts between them, it coordinates the actions of the State Pollution Control Boards.¹⁴ In the years 2000, 2003, 2011, the BMW 1998 regulations faced amendments. Due to the lack of agreement on classification and standards, the document of the BMW guidelines for 2011 was left as a draught and was not made public.¹⁵ The Biomedical Waste Management Rules 2016, which replace BMW rule 1998, were published by GOI in response to later revisions to the previous BMW rules.¹⁴⁻¹⁵

2016 Biomedical Waste Rules: Key Features

The intent of the rules has been broadened to cover a variety of health camps, including immunization, blood donation, and surgical camps. The occupant of an HCF's responsibilities have changed. The second major changes come in the duty of an occupier. The individual who has administrative responsibility over the HCF that is producing BMW is the occupier. According to 2016 rule the laboratory waste, microbiological waste, and blood bags must undergo mandatory pre-treatment before disposal either at CBMWTF or

on-site.¹⁶ It is recommended that the sterilization/disinfection procedure adhere to National AIDS Control Organization (NACO) or WHO guidelines. Every HCF has been instructed to gradually stop using chlorinated plastic bags, gloves, and blood bags within the next two years in order to stop the release of dangerous dioxins and furans while burning such wastes. In addition, the new regulation mandates the inclusion of bar codes for better tracking and identification on all bags and containers used for BMW treatment and disposal.¹⁶ All the health care facilities instructed to immunize the health care workers against Hepatitis B and Tetanus and provide training on BMW rules and handling. In addition, all significant accidents, including those brought on by fire risks, blasts, handling BMW, and corrective action taken by the required authority, should be reported and are required to maintain and update on day-to-day basis the bio-medical waste management register and display the monthly record of BMW. To facilitate segregation and eliminate misunderstanding caused by the earlier high number of categories, the 2016 announcement further reduces the number of categories to four. The Ministry of Environment and Forests (MoEF) would examine HCFs once a year through state health secretaries, the State Pollution Control Boards (SPCB), and the Central Pollution Control Board, in contrast to the 2011 guidelines, that did not include a provision for a monitoring authority (CPCB).¹⁶ If a Common Biomedical Waste Treatment Facility (CBMWTF) is available at a distance of 75 kilometres, no HCF may build an on-site BMW treatment and disposal facility. If no CBMWTF is available, the occupier must install the necessary BMW treatment facility, such as an incinerator, autoclave, microwave, or shredder, after obtaining prior approval from the required authority.¹⁶

The amendments bring more clarifications in BMW and make improving in segregation, transport, and disposal of waste by increasing the coverage and simplified the authorization. In order to strengthen the application of environmentally

sound management of biomedical waste in India and underline the effort to safeguard the environment and human health from infectious biomedical waste, the 2016 Rules have been revised once in 16th March 2018, 20th Feb 2019 and 10th May 2019. The modifications state that after March 27, 2019, chlorinated plastic gloves and bags are no longer permitted. The phase out of blood bags has been waived in compliance with the 2018 revisions to the BMW regulations.¹⁷

Bio Medical Waste Management Scenario in Pre Covid-19

According to the 2016 BMW Rules, there must be enough CBWTFs put up to cover the entire state or all HCFs in order to treat and dispose of biomedical waste. 2018 Annual report states that there 200 total number of CBWTFs in the country and 12,326 captive treatment facilities installed by HCFs.¹⁸ About 614 tonnes of bio-medical waste are produced each day overall, of which 534 tonnes are handled in CBWTFs and captive treatment facilities. It would suggest that 80 tonnes are left untreated. There are enough CBWTFs in the states of Uttar Pradesh, Tamil Nadu, Andhra Pradesh, Chandigarh, Madhya Pradesh, Punjab, and Haryana. However, the report suggests that during the period 2006 to 2018, the use of captive waste treatment incinerators was reduced from 225 to 120, and the CBWTF was increased from 155 to 200. Several states, including Andaman & Nicobar, Assam, Arunachal Pradesh, Chhattisgarh, Goa, Himachal Pradesh, Jharkhand, Karnataka, Lakshadweep, Manipur, Meghalaya, Sikkim, Mizoram, Nagaland, Odisha, Rajasthan, Kerala, Tamil Nadu, Tripura, & Uttarakhand, use deep burials to dispose of biomedical waste, which is not recommended as per CPCB guidelines. The status of Biomedical Waste Management (BMW) scenario in India before Covid-19 is shown in Table 1.¹⁸

Status of Bio Medical Waste Scenario in India: Before Covid-19

(CPCB Annual Report 2018)

Table 1: CPCB Annual Report 2018

No. of Health care Facilities (HCFs)	2,70,416
No. of bedded HCFs	97,382
No. of Non-bedded HCFs	1,73,831
No. of beds	22,06,362
No. of CBWTFs	200*+28**
No. of HCFs granted authorization	1,10,356
No. of HCFs having Captive Treatment Facilities	12,326

No. of Captive Incinerators Operated by HCFs	120
Quantity of bio-medical was tegeneratedin Tones / day	614
Quantity of bio-medical was tetreated in Tones/day	534
No. of HCFs violated BMW Rules	27,301
No. of Show-cause notices /Directions issued to defaulter:	16,956HCFs

COVID 19 SCENARIO IN INDIA

The first cases of COVID-19 in India were reported on 30th January 2020.¹⁹ Lock down was the initial strategy taken by the GOI to prevent and control the pandemic; however, number of cases were increased and followed by this surge of cases the effective biomedical waste management become the prime concern of many developing countries including in India.²⁰ The Central Pollution Control Board (CPCB), has released guidelines for handling, treatment and safe disposal of BMW generated during treatment, diagnosis and quarantine of patients confirmed or suspected to have the novel coronavirus disease (COVID-19).²¹ These recommendations are based on the most

recent understanding of COVID-19 and procedures now in use for the management of infectious waste produced in hospitals during the treatment of viral and other contagious diseases like HIV, H1N1, etc. Number of amendments came into act referred as Revision 1, Revision 2, Revision 3, Revision 4 and Revision 5, need assessment make all these revisions.²¹

Disposal of Solid Biomedical Waste

- ❖ The instructions include using double layered bags in the COVID-19 isolation sections and color coded bins for onsite segregation. For disposable PPEs, gloves, and masks, there should be additional, temporary bins in addition to the usual containers (e.g., N95 mask for cleaning and sterilization).²²



Source: CPCB

- ❖ The confirmed COVID-19 positive patient's feces should be collected in a diaper and classified as yellow category BMW, or they can be collected in a pan and flushed in the toilet. For handling the BMW at COVID-19 sites, special carrier trolley and segregation bags should be available.²²
- ❖ For better assessment, handling, and disposal of BMW, the bags and containers should be clearly labelled as "COVID-19."



Source: AIIMS, Delhi

- ❖ Daily cleaning should be done with a 1-2% sodium hypochlorite solution on the exterior and interior of the containers and trolleys. A separate record should be maintained for BMW generated from COVID-19 related activities.²²
- ❖ The necessary training and personal safety equipment should be provided to all

individuals involved in the handling of BMW (COVID-19). These persons ought to abide by the standard operating procedures, practice good cleanliness and infection prevention practises, and go through routine health examinations. Education, training, and awareness should be provided alongside this on a consistent basis.²²

- ❖ The central pollution control board's official app (COVID-19 BWM) can be downloaded by facilities, who can then register in the app and easily upload their information.
- ❖ The transportation of BMW should be done in special vehicles that are disinfected after each trip. In an effluent treatment plant, liquid waste should be treated chemically, and the disinfection procedure should guarantee the inactivation of coronaviruses.²³⁻²⁴

BMW Transport Vehicle



Source: CPCB

Disposal of liquid waste and waste water from hospitals and laboratories

Due to its physical nature, liquid trash is managed differently than solid waste, hence the procedures used to handle solid waste do not apply to liquid waste. The treatment of the liquid waste is the responsibility of every healthcare facility running a STP as well as the terminal sewage plant operators. The hospital and all involved in its handling should make sure that the coronavirus is inactivated or killed. The SOPs established by the pollution control board must be rigorously adhered to by all STP. PPE should be worn by the employees managing the wastewater treatment process. During the pandemic, it is possible to avoid using the STP's treated water.²²⁻²⁴

Annual Report Information: A Comparison with Previous year 2019 and 2020

Over time, there are more healthcare institutions



Source: CPCB

than ever before. The total number of healthcare facilities was 3,22,425 in 2019; however, this figure has now climbed to 3,52,014 with increase in the number of beds. Out of the 3,52,014 HCFs, 1,60,736 HCFs are authorized, reflecting an increase in the overall number of healthcare facilities.²⁵ The overall amount of biomedical waste produced per day was estimated to be 774 tonnes, of which 656

tonnes per day were non-COVID biomedical waste and 118 tonnes per day were COVID biomedical waste. The number of common biomedical waste treatment facilities has increased from 202 to 208, while the number of captive treatment facilities has reduced from 18,015 to 17,206 for the treatment and disposal of generated biomedical waste.²⁵ Detailed comparison on biomedical waste management scenario is given below.²⁵

CPCB Annual Report 2019 & 2020

Particulars	Year 2019	Year 2020
No. of HCFs	3,22,42	35,20,14
No. of Bedded HCFs	1,06,796	1,13,186
No. of Non-bedded HCFs	2,15,780	2,37,938
No. of Beds	24,86,327	2,5,44,116
No. of CBWTFs	202	208
No. of HCFs Utilizing CBWTFs	2,35,571	2,44,282
Number of HCFs granted authorization	1,53,885	1,60,736
No. of HCFs having Captive Treatment Facilities	18,015	17,206
No. of Captive Incinerators Operated by HCFs	136	125
Quantity of bio-medical waste generated in Tonnes/day	619	774
Quantity of bio-medical waste treated in Tonnes/day	544	708
No. of HCFs violated BMW Rules	29,062	22,261
No. of Show-Cause notices/Directions issued to defaulter HCFs	17,435	13, 389

According to information provided in the SPCBs/ PCCs' annual reports for the year 2020, there are now 208 CBWTFs operating in the nation, and 33 more are being built. There are no CBWTFs for the treatment and disposal of biomedical waste in the following states: Andaman & Nicobar, Arunachal Pradesh, Goa, Ladakh, Mizoram, Nagaland, Sikkim, and Tripura. However, CPCB asked the above mentioned State Boards to submit a proposal for the construction of CBWTFs so that they may receive funding from the Ministry of Environment, Forests, and Climate Change.²⁶

CONCLUSION

Proper Biomedical waste management (BMWM) is not just a legal necessity but also a social responsibility. Management of biomedical wastes is one of the major social responsibilities of individuals as well as Government / State officials. For the proper management of biomedical waste there is a need for thorough sensitization of health care professionals as well as community members using behavior change and communication (BCC) and information education and communication technique (IEC) on a regular basis. Certain precautionary measures and protocols should

be followed as a part of BMWM which include vaccination against Hepatitis B, provision of appropriate personnel protective equipment's (PPEs), and maintenance and managements of records. Biomedical waste, if not managed properly, will pose significant environmental and health impact. Recommend monitoring and legal action as significant steps in the management of biomedical wastes.

REFERENCES

1. Sarwal R; Prasad U; Madangopal K; Kalal S; Kaur D; Kumar A; Regy P; Sharma J. Investment Opportunities in India's Healthcare Sector. NITI Aayog. March 2021.
2. Hegde, V., Kulkarni, R.D. & Ajantha, G.S., 2007. Biomedical Waste Management. Journal of Oral and Maxillofacial Pathology, 11(1), p.5.
3. Manzoor J, Sharma M. Impact of biomedical waste on environment and human health. Environmental Claims Journal. 2019;31(4):311-34.
4. The 17 goals | sustainable development [Internet]. United Nations. United Nations; [cited 2022Sep22]. Available from: <https://sdgs.un.org/goals>.
5. Guidelines for Management of Healthcare Waste as per Biomedical Waste Management Rules, 2016

- [Internet]. 2022 [cited 29 June 2022]. Available from: https://cpcb.nic.in/uploads/Projects/Bio-Medical-Waste/Guidelines_healthcare_June_2018.pdf.
6. Health-care waste [Internet]. Who.int. 2022 [cited 29 June 2022]. Available from: <https://www.who.int/news-room/fact-sheets/detail/health-care-waste>.
 7. WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health care settings [Internet]. 2022 [cited 29 June 2022]. Available from: <https://apps.who.int/iris/bitstream/handle/10665/250144/9789241549820-eng>.
 8. Hauri A, Armstrong G, Hutin Y. The global burden of disease attributable to contaminated injections given in health care settings. *International Journal of STD & AIDS* [Internet]. 2004;15(1):7-16. Available from: <https://pubmed.ncbi.nlm.nih.gov/14769164/>
 9. Bio-medical waste management: situational analysis & predictors of performances in 25 districts across 20 Indian States [Internet]. PubMed Central (PMC). 2022 [cited 29 June 2022]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994730/>
 10. Coronavirus cases: [Internet]. Worldometer. [cited 2022Sep22]. Available from: <https://www.worldometers.info/coronavirus>
 11. Das AK, Islam MN, Billah MM, Sarker A. Covid-19 pandemic and Healthcare Solid Waste Management strategy – a mini-review. *Science of The Total Environment*. 2021;778:146220.
 12. Dehal A, Vaidya AN, Kumar AR. Biomedical waste generation and management during COVID-19 pandemic in India: Challenges and possible management strategies. *Environmental Science and Pollution Research*. 2021;29(10):14830–45.
 13. Patrício Silva AL, Prata JC, Walker TR, Campos D, Duarte AC, Soares AMVM, et al. Rethinking and Optimising Plastic Waste Management under covid-19 pandemic: Policy Solutions based on redesign and reduction of single-use plastics and personal protective equipment. *Science of The Total Environment*. 2020;742:140565.
 14. Central Pollution Control Board [Internet]. CPCB. [cited 2022Sep22]. Available from: <https://cpcb.nic.in/rules-3>.
 15. Datta P, Mohi G, Chander J. Biomedical Waste Management in India: Critical appraisal. *Journal of Laboratory Physicians*. 2018;10(01):006–14.
 16. Biomedical Waste Management Rules 2016 [Published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i)] Central Pollution Control Board [Internet]. CPCB. [cited 2022 Sep22]. Available from: <https://cpcb.nic.in/rules-3>.
 17. The principal rules were published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section dated the 28th March, 2016 and subsequently amended vide number G.S.R. 234, [cited 2022 Sep22]. Available from: <https://cpcb.nic.in/rules-3>.
 18. On biomedical waste management as per biomedical waste management rules ... [Internet]. [cited 2022 Sep24]. Available from: https://www.cpcb.nic.in/uploads/Projects/Bio-Medical-Waste/AR_BMWM_2018.pdf
 19. Ghosh A, Nundy S, Mallick TK. How India is dealing with covid-19 pandemic. *Sensors International*. 2020;1:100021.
 20. Ilyas S, Srivastava RR, Kim H. Disinfection technology and strategies for COVID-19 hospital and bio-medical waste management. *Science of The Total Environment*. 2020;749:141652.
 21. CPCB | Central Pollution Control Board [Internet]. [cited 2022Sep25]. Available from: <https://www.cpcb.nic.in/covid-waste-management/>
 22. Chand S, Shastry CS, Hiremath S, Joel JJ, Krishnabhat CH, Mateti UV. Updates on biomedical waste management during COVID-19: The Indian scenario. *Clinical Epidemiology and Global Health*. 2021; 11:100715.
 23. CPCB | Central Pollution Control Board [Internet]. [cited 2022 Sep25]. Available from: https://www.cpcb.nic.in/uploads/Projects/Bio-Medical-Waste/SOP_covid_1.pdf
 24. Central Pollution Control Board [Internet]. [cited 2022 Sep25]. Available from: https://www.cpcb.nic.in/uploads/Projects/Bio-Medical-Waste/BMW-Guidelines-Covid_2.pdf
 25. On biomedical waste management as per biomedical waste ... CPCB [Internet]. [cited 2022 Sep25]. Available from: https://cpcb.nic.in/uploads/Projects/Bio-Medical-Waste/AR_BMWM_2020.pdf
 26. Common bio-medical waste treatment and disposal facility [Internet]. Press Information Bureau. [cited 2022 Sep25]. Available from: <https://www.pib.gov.in/PressReleasePage.aspx?PRID=1807735>.

SUBSCRIPTION FORM

I want to renew/subscribe international class journal “**RFP Indian Journal of Hospital Infection**” of Red Flower Publication Pvt. Ltd.

Subscription Rates:

- Institutional: **INR 13500 / USD 1054.69**

Name and complete address (in capitals): _____

Payment detail:

Online payment link: <http://rfppl.co.in/payment.php?mid=15>

Cheque/DD: Please send the US dollar check from outside India and INR check from India made payable to ‘Red Flower Publication Private Limited’. Drawn on Delhi branch.

Wire transfer/NEFT/RTGS:

Complete Bank Account No. 604320110000467

Beneficiary Name: Red Flower Publication Pvt. Ltd.

Bank & Branch Name: Bank of India; Mayur Vihar

MICR Code: 110013045

Branch Code: 6043

IFSC Code: BKID0006043 (used for RTGS and NEFT transactions)

Swift Code: BKIDINBBDOS

Term and condition for supply of journals

1. Advance payment required by Demand Draft payable to **Red Flower Publication Pvt. Ltd.** payable at **Delhi**.
2. Cancellation not allowed except for duplicate payment.
3. Agents allowed 12.5% discount.
4. Claim must be made within six months from issue date.

Mail all orders to

Subscription and Marketing Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India)

Phone: 91-11-79695648

Cell: +91-9821671871

E-mail: sales@rfppl.co.in

BHIM BOI UPI QR

SCAN HERE TO PAY
WITH ANY BHIM UPI APP



RED FLOWER PUBLICATIONS PRIVATE LIMITED

boism-9718168299@boi

STATEMENT ABOUT OWNERSHIP AND OTHER PARTICULARS

“RFP Indian Journal of Hospital Infection” (See Rule 8)

1. Place of Publication : Delhi
2. Periodicity of Publication : Quarterly
3. Printer's Name : **Dinesh Kumar Kashyap**
Nationality : Indian
Address : 3/259, Trilokpuri, Delhi-91
4. Publisher's Name : **Dinesh Kumar Kashyap**
Nationality : Indian
Address : 3/259, Trilokpuri, Delhi-91
5. Editor's Name : **Dinesh Kumar Kashyap**
Nationality : Indian
Address : 3/259, Trilokpuri, Delhi-91
6. Name & Address of Individuals : **Red Flower Publication Pvt. Ltd.**
who own the newspaper and particulars of : 41/48, DSIDC, Pocket-II
shareholders holding more than one per cent : Mayur Vihar, Phase-1, Delhi-91
of the total capital

I, **Dinesh Kumar Kashyap**, hereby declare that the particulars given above are true to the best of my knowledge and belief.

Sd/-
(**Dinesh Kumar Kashyap**)

RFP Indian Journal of Hospital Infection

Library Recommendation Form

If you would like to recommend this journal to your library, simply complete the form given below and return it to us. Please type or print the information clearly. We will forward a sample copy to your library, along with this recommendation card.

Please send a sample copy to:

Name of Librarian

Name of Library

Address of Library

Recommended by:

Your Name/ Title

Department

Address

Dear Librarian,

I would like to recommend that your library subscribe to the RFP Indian Journal of Hospital Infection. I believe the major future uses of the journal for your library would provide:

1. Useful information for members of my specialty.
2. An excellent research aid.
3. An invaluable student resource.

I have a personal subscription and understand and appreciate the value an institutional subscription would mean to our staff.

Should the journal you're reading right now be a part of your University or institution's library? To have a free sample sent to your librarian, simply fill out and mail this today!

Stock Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India)

Phone: 91-11-79695648

Cell: +91-9821671871

E-mail: sales@rfppl.co.in

Antimicrobial Resistance and Antimicrobial Stewardship

Sayan Bhattacharyya

How to cite this article:

Sayan Bhattacharyya/Antimicrobial Resistance and Antimicrobial Stewardship/RFP Indian Journal of Hospital Infection, 2023,5(1):19–22.

Abstract

Antimicrobial resistance (AMR) is a real problem across the world. In fact, it is fast emerging as a pandemic. Bacteria acquire resistance antibiotics by many mechanisms. However, AMR also exists in parasites and fungi. Strategic plans and concerted efforts are needed to counter the exceedingly high burden of AMR.

Keywords: Antibiotic; Antimicrobial; Stewardship.

INTRODUCTION

Antimicrobials are a boon to the medical world. Antimicrobial stewardship is the need of the hour, keeping in mind the mounting cases of AMR or Antimicrobial resistance across the world. The problem is especially acute in developing countries of South East Asia, Africa and South America. It is estimated that by 2050, the total number of deaths due to AMR will be higher than deaths due to cancer and road traffic accidents, combined. Only two new classes of antibiotics have come up in the last decade. The development of new antibiotics needs

time and lot of money. Hence existing antibiotics should be used cautiously and judiciously.

Antimicrobial resistance due to antimicrobial misuse was predicted long ago by Alexander Fleming, the discoverer of the first natural antibiotic, Penicillin. Now, many bacteria causing infections are resistant to one or more classes of antibiotics. The antibiotic resistance is more pronounced in Gram negative bacteria. However, it is also common in Gram positive bacteria like *Staphylococcus aureus* and *Enterococcus* spp. Often clinicians have to resort to last line antibiotics like Vancomycin and Colistin for treating drug-resistant bacteria. These pathogens which are notorious for antibiotic resistance are also termed by the acronym ESKAPE pathogens (*Enterococcus* spp., *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Escherichia coli*). They mostly cause nosocomial infections but can also lead to community acquired infections. Interestingly, AMR is a problem not only in the hospital set up but also in the community. According to our own experience, now about 30–46% of uropathogenic *Escherichia coli* from the community are resistant in vitro to Nitrofurantoin, a drug commonly used to treat UTI.

Author Affiliation: Associate Professor, Department of Microbiology, All India Institute of Hygiene and Public Health, Kolkata, West Bengal 700098, India.

Correspondence Author: Sayan Bhattacharyya, Associate Professor, Department of Microbiology, All India Institute of Hygiene and Public Health, Kolkata, West Bengal 700098, India.

E-mail: sayantheboss@yahoo.co.in

Received on: 09.12.2022

Accepted on: 16.02.2023

The role played by environment in AMR

In India open air defecation is still very common in remote villages and this can disseminate drug resistant pathogens into the soil and water.¹ Use of antibiotics in crop production, as manure and in animal husbandry also compounds the problem and makes persistence of multi drug resistant bugs in the environment easier.² Poor sanitation, effluents from the pharmaceutical industry and healthcare facilities also renders persistence of antibiotic resistant bacteria easier.² In 2021, the WHO, World Organization for Animal Health, FAO and UNEP (United Nations Environmental Program) joined hands to form the One Health quadripartite to combat the health risks including AMR, at the human, animal and plant ecosystem interface.²

Key players for high burden of AMR

Several things go into attaining the high burden of AMR in clinical settings, like poor knowledge of antibiotics among the masses, improper implementation of the regulatory acts, improper drug - drug combinations and many other reasons. Other factors can be listed below:

- a. Consumption of antibiotics in inadequate doses.
- b. Consuming antibiotics when not at all necessary.
- c. Availability of antibiotics over the counter.
- d. Using antimicrobials as daily injection, thus reducing compliance.
- e. Using antibiotics empirically, without sufficient knowledge of susceptibility pattern of common pathogens in the given area.
- f. Improper escalation and de-escalation of antibiotics.
- g. Lack of knowledge of difference between in vivo and in vitro susceptibility of pathogens to antimicrobials.
- h. Budgetary constraints hampering proper surveillance of AMR.³
- i. Health systems in low income and middle-income countries often have less functional and infrastructural resources to cater to a large population, more so in rural areas, and there universal access to primary healthcare services and antibiotics becomes a major challenge.

- j. Prescribing of antibiotics by unqualified medical practitioners or quacks in many peripheral areas.
- k. Poor educational status and low awareness among people lead to many myths which can promote self-medication of antibiotics.
- l. Hospital acquired bacterial pathogens often possess biofilms comprising bacterial colonies and exopolymeric matrix (EPM), which impairs penetration of antibiotics to the bacterial cells.
- m. Use of antibiotics like Colistin and colistimethate rampantly in animal husbandry and also as growth promoters leads to dissemination of dangerous drug-resistant bugs in the community.

ANIMAL HUSBANDRY AND AMR

Antibiotics are often used inadvertently and sometime purposefully in animal husbandry. The use of the antibiotic Avoparcin in food of animal in Europe was primarily responsible for spread of VRE or Vancomycin resistant Enterococci across the world. Effluents from the abattoirs and animal facilities can contain high load of drug resistant bacteria which get mixed with soil and water and thus can spread AMR to man also.

The pathogens which top the table in AMR

Among bacteria, Methicillin resistant *Staphylococcus aureus* or MRSA tops the list of pathogens having high load of AMR, followed by multidrug resistant excluding extensively drug resistant tuberculosis (MDR TB), third generation cephalosporin resistant *E-coli*, carbapenem resistant *Acinetobacter baumannii*, fluoroquinolone resistant *E-coli*, carbapenem resistant *K pneumoniae*, and third generation cephalosporin resistant *K pneumoniae*.⁴

Among the pathogenic fungi, non-albicans *Candida*, particularly *Candida auris* is notorious for exhibiting antifungal resistance to many antifungal classes of compounds. They are always resistant to Fluconazole. Among parasites, *Plasmodium falciparum* and *Leishmania donovani* are often resistant to the available antimicrobials. Among viruses, HIV is notorious for developing resistance to HAART in cases of poor compliance.

Mechanisms of Antimicrobial resistance in microbes

Many mechanisms are there for antibiotic resistance in microbes. In bacteria, the common mechanisms are thickening of cell wall (as in VISA or Vancomycin indeterminate *Staphylococcus aureus*), altered antibiotic binding site in cell wall or ribosomes (as in MRSA or aminoglycoside or macrolide resistant bacteria). Sometimes, antibiotics are broken down by enzymes of bacteria, as in Beta-lactamases (like ESBL and metallo beta-lactamases) expressed by gram negative bacteria like *Escherichia coli* and *Klebsiella pneumoniae*. Aminoglycoside-modifying enzymes confer resistance to this group of drugs in *Enterococcus* spp.

How to reduce the menace of AMR

Health education is the primary step to reduce the high burden of AMR. Other things like antibiotic stewardship and practising this stewardship will help in reducing the high load of AMR in the community.

Antibiotic ward rounds are also a good way to mitigate the load of AMR. In this, a team of clinicians, laboratory scientists or microbiologist and nurses carry out rounds of patients admitted to the hospital and scrutinize their antibiotic prescriptions for proper dosage and adverse effects keeping in mind their pre-existing health conditions. Pharmacodynamics of a particular drug are also important things to be remembered before prescribing it. India has a National Action Plan on Antimicrobial Resistance. Our national policy for containment of AMR was introduced in 2011. India also saw the Delhi Declaration on AMR, which was endorsed at the Inter-Ministerial Consultation on AMR in April 2017.⁵ India also has National action plan on A3MR (NAP) promulgated in 2021, to counter the challenge of AMR, by 6 key mechanisms which include training, spreading awareness about AMR, Information education communication (IEC) activities and other means. Antivirulence strategies or drugs, and also novel therapeutic options like efflux pump inhibitors, also may play a role in the future to bring down the cases of AMR. Awareness programs about AMR and antibiotic awareness week observation can also play decisive role in promoting safe and judicious use of extant antimicrobials. Global action plan and also GLASS are good initiatives to combat AMR. Most importantly, a concerted effort by medical professionals, veterinarians and environmentalists

should generate a holistic or one health view point for managing AMR.

DISCUSSION

AMR is a real public health problem across the world, especially in the developing countries of Asia, South America and Africa. It would not be wrong to put it as the next pandemic to hit the world very soon. In 2008, about 29% of isolates of *Staphylococcus aureus* were found to be methicillin resistant across the World, and by 2014, this figure rose to a whopping 47%.⁵ All governments must try and collaborate to bring down the burden of AMR. It affects Gross domestic product adversely, and also imparts a substantial financial burden to the patient.⁶ In fact, only AMR can be held responsible for causing loss of about 700000 lives a year.³ Many factors are responsible for such high burden of AMR, like antibiotic misuse and abuse. In fact, antibiotic misuse, overuse, and improper hygiene and sanitation along with poor implementation of infection control policy are the major drivers for AMR across the world. It had been reported that about 70% of medically important antimicrobial compounds are approved for use in veterinary practice.⁷ This can lead to a grave situation of antibiotic resistance in most bacterial pathogens. The "ESKAPE" pathogens mentioned earlier cause most of drug resistant nosocomial infections. However now other emergent pathogens are also coming up, like *Clostridium difficile*, carbapenem-resistant *Enterobacteriaceae* (CRE) and drug-resistant *Neisseria gonorrhoeae* which have been reported by US Centers for Disease Control and Prevention (CDC).⁸ Vaccination for infections, wherever applicable, and also proper biomedical waste disposal, may also be pivotal for control of antimicrobial resistance. Maintaining good hygiene and proper handwashing alone can bring reduce infections and usage of antimicrobials by about 40%.³ In this way, pneumococcal vaccination, wherever applicable, can bring down the burden of cases of antibiotic resistant *Pneumococcal* infections by half or even more.³

Other things like including AMR in medical and paramedical curricula may also be helpful. Nurses and other healthcare providers also need to be educated about AMR and infection control to make control of AMR a success. We also need to publish more and more scientific data on the epidemiology and newer diagnostic methods of AMR. At this moment, the development of an effective in-hospital surveillance and antimicrobial stewardship with

unified antimicrobial protocols also seems to be the need of the hour.⁵ This can be carried out by the hospital infection control committee. Surveillance for AMR is also needed very badly. The National policy on AMR in India has recommend 3 types of surveillances, namely comprehensive surveillance, sentinel surveillance and point prevalence.⁹ We must also promote new and rapid diagnostics to allay misdiagnosis of infections and thus enhance proper antibiotic usage.¹⁰ Clinicians must use broad spectrum antibiotics sparingly, and escalate and deescalate antibiotics judiciously. Overall, we must also act the community level to make more people aware of the perils of AMR. Public should be more aware of antibiotics and the need to use them sparingly and judiciously. The US government performed the AMR Challenge from 2018 to 2019 using a one health approach, to accelerate the fight against AMR. More such efforts are needed. Concordant with the theme of World antibiotic awareness week 2022, people of diverse disciplines must converge and act together in the wake of one health, to bring down the high burden of AMR.

CONCLUSION

AMR is a real cause for worry and if not tackled now, it is likely to become a major headache for clinicians as well as laboratory people. All must try to bring down AMR to manageable levels by proper diagnostics, spreading awareness and promoting antibiotic stewardship.

REFERENCES

1. Taneja N, Sharma M. Antimicrobial resistance in the environment: The Indian scenario. *Indian J Med Res* 2019;149: 119-128. doi: 10.4103/ijmr.IJMR_331_18.
2. Bagai A, Dutt D, Dharmshaktu N. Antimicrobial resistance: Here's what can be done to address environmental AMR in India. <https://www.downtoearth.org.in/blog/health/antimicrobial-resistance-here-s-what-can-be-done-to-address-environmental-amr-in-india-86307>.
3. Pokharel S, Raut S, Adhikari B. Tackling antimicrobial resistance in low-income and middle-income countries *BMJ Global Health* 2019;4:e002104.
4. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* 2022;399:629-655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0).
5. Gunasekaran K. Antimicrobial resistance in India – "A silent pandemic within the pandemic. *Current Med Issues* 2022;20(3):123-124.
6. Naylor, N.R., Atun, R., Zhu, N. et al. Estimating the burden of antimicrobial resistance: a systematic literature review. *Antimicrob Resist Infect Control* 7, 58 (2018). <https://doi.org/10.1186/s13756-018-0336-y>.
7. US Food and Drug Administration Summary report on antimicrobial sold or distributed for use in food producing animals, 2017. Available: <https://www.fda.gov/media/119332/download> [Accessed 6 Aug 2019].
8. Uchil RR, Kohli GS, Katekhaye VM, Swami OC. Strategies to Combat Antimicrobial Resistance. *J Clin Diag Res* 2014;8(7):ME01-04. DOI: 10.7860/JCDR/2014/8925.4529.
9. National Policy for Containment of Antimicrobial Resistance, Directorate General of Health Services, Ministry of Health & Family Welfare, India 2011.
10. Sirec T, Benedyk T. One Health: 10 ways to tackle antimicrobial resistance. <https://fems-microbiology.org/one-health-10-ways-to-tackle-antibiotic-resistance/> . last accessed 07.12.2022.

Instructions to Authors

Submission to the journal must comply with the Guidelines for Authors.
Non-compliant submission will be returned to the author for correction.

To access the online submission system and for the most up-to-date version of the Guide for Authors please visit:

<http://www.rfppl.co.in>

Technical problems or general questions on publishing with **IJHI** are supported by Red Flower Publication Pvt. Ltd.'s Author Support team (http://rfppl.co.in/article_submission_system.php?mid=5#)

Alternatively, please contact the Journal's Editorial Office for further assistance.

Editorial Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India)

Mobile: 9821671871, Phone: 91-11-79695648

E-mail: author@rfppl.co.in

Red Flower Publication Pvt. Ltd.

CAPTURE YOUR MARKET

For advertising in this journal

Please contact:

International print and online display advertising sales

Advertisement Manager

Phone: 91-11-79695648, Cell: +91-9821671871

E-mail: info@rfppl.co.in

Recruitment and Classified Advertising

Advertisement Manager

Phone: 91-11-79695648, Cell: +91-9821671871

E-mail: info@rfppl.co.in

A Study of Malaria in National Capital Territory (NCT) of Delhi

Arvind Nath

How to cite this article:

Arvind Nath/A Study of Malaria in National Capital Territory (NCT) of Delhi/RFP Indian Journal of Hospital Infection, 2023,5(1):25–27.

Abstract

Background: To the best knowledge of the author, there is no available literature on the status of Malaria in NCT of Delhi. Hence the preparation of this document.

Objectives: To find out the parameters of Malaria in NCT of Delhi till as recently as possible.

Methods: By studying the documents prepared by the National Centre for Vector Borne Diseases (NCVBD) and doing a web search on Malaria in NCT of Delhi.

Results: It is seen that the Annual Parasite Incidence (API) of Malaria in NCT of Delhi had come down to the very low level of 0.02 in 2018 and that there were only 102 cases of Malaria in NCT of Delhi during 2021 as of September 28th of that year.

Conclusions: NCT of Delhi is very close to achieving near-elimination goals but will have to take active measures to reach it.

Keywords: Malaria; Delhi; API; NCVBD; WHO.

INTRODUCTION

NCT of Delhi is in the northern part of India. It is bordered by Haryana in the North, West and South and by Uttar Pradesh in the East.

MATERIAL & METHODS

The study design included analysis of the annual reports of the Malaria Division of the National Centre for Vector Borne Diseases Control (NCVBDC) for 2017 and 2018 and a web search for information on Malaria in NCT of Delhi.

RESULTS

According to the most recent data available on the NCVBDC website (data for 2018), the API for NCT of Delhi was 0.02.² It's comparison with the API from 2017 can be seen from the following table:

Further search revealed the following information on Malaria cases in NCT of Delhi during 2019, 2020

Author Affiliation: Scientist 'E', ICMR National Institute of Malaria Research, New Delhi 110077, India.

Correspondence Author: Arvind Nath, Scientist 'E', ICMR National Institute of Malaria Research, New Delhi 110077, India.

E-mail: nath.hq@icmr.gov.in

Received on: 16.08.2022

Accepted on: 20.10.2022




Fig. 1: Map of NCT of Delhi [Source: (1)]

and 2021 and is shown in the following table:

Table 1: API of NCT of Delhi, 2017 and 2018

Union Territory	Year	
	2017	2018
NCT of Delhi	0.03	0.02

Sources: (2) and (3)

Table 2: Data on Malaria Cases in NCT of Delhi, 2019, 2020 and 2021

Reference Period	Number of Malaria Cases
January 1, 2019, to August 17, 2019	111
January 1, 2020, to September 25, 2020	149
January 1, 2021, to September 28, 2021	102

Sources: (4) and (5)

DISCUSSION

Beginning in 2017, there is a decline in the incidence of malaria in NCT of Delhi with a mild increase during 2020.

In 2016, the Government of India adopted a framework for Malaria Elimination in India covering the period 2016 – 2030.⁶ This was based on WHO's Global Technical Strategy for Malaria covering the period 2016 – 2030 which was adopted in 2015 and updated in 2021.⁷

The aim is to reach zero Malaria cases by 2027 and then wait for three years before WHO can grant Malaria-free status certification. It is already nearly the middle of 2022 and India is about to reach the halfway mark of the period from 2016 to 2027.

CONCLUSION

Although NCT of Delhi did not reach zero Malaria cases in 2021, it did reach an API of 0.02 during 2018. Therefore, it is a good candidate for being the first administrative territory in the country close to being able to achieve near elimination goals.

Acknowledgements: Nil

Source of Funding: Nil

Conflict of Interest: There is no conflict of interest.

REFERENCES

1. Registrar General and Census Commissioner of India 2011. Map of NCT of Delhi. Available at <https://censusindia.gov.in/nada/index.php/catalog/40> Accessed on 30 May 2022.
2. Government of India. Annual Report of National Vector-Borne Disease Control Programme 2018. Available from: <https://nvbdcp.gov.in/Doc/Annual-Report-2018.pdf> Accessed on 25 August 2021.
3. Government of India. Annual Report of National Vector-Borne Disease Control Programme 2017. Available at <https://nvbdcp.gov.in/Doc/Annual-Report-2017.pdf> Accessed on 31 August 2021.
4. <https://www.hindustantimes.com/cities/111-malaria-cases-reported-in-delhi-double-that-of-dengue/story-yDNNUOvNOr5tP0daY5U1VN.html> Accessed on 30 May 2022.
5. <https://timesofindia.indiatimes.com/city/delhi/malaria-cases-cross-100-mark-for-the-season/articleshow/86569260.cms> Accessed on 30 May 2022.
6. Government of India. National Framework for Malaria Elimination in India 2016 – 2030. Available at <https://nvbdcp.gov.in/WriteReadData/l892s/National-framework-for-malaria-elimination-in-India-2016%E2%80%932030.pdf> Accessed on 17 September 2021.
7. World Health Organization. Global Technical Strategy for Malaria 2016 – 2030. Available at <https://www.who.int/publications/i/item/9789240031357> Accessed on 17 September 2021.

REDKART.NET

(A product of Red Flower Publication (P) Limited)

(Publications available for purchase: Journals, Books, Articles and Single issues)

(Date range: 1967 to till date)

The Red Kart is an e-commerce and is a product of Red Flower Publication (P) Limited. It covers a broad range of journals, Books, Articles, Single issues (print & Online-PDF) in English and Hindi languages. All these publications are in stock for immediate shipping and online access in case of online.

Benefits of shopping online are better than conventional way of buying.

1. Convenience.
2. Better prices.
3. More variety.
4. Fewer expenses.
5. No crowds.
6. Less compulsive shopping.
7. Buying old or unused items at lower prices.
8. Discreet purchases are easier.

URL: www.redkart.net

Subscription Information

India

Institutional (1 year) (Print+Online): INR 13500

Rest of the World

Institutional (1 year) (Print+Online): \$ 1054.69

Payment instructions Online payment link:

<http://rfppl.co.in/payment.php?mid=15>

Cheque/DD:

Please send the US dollar check from outside India and INR check from India made payable to 'Red Flower Publication Private Limited'. Drawn on Delhi branch

Wire transfer/NEFT/RTGS:

Complete Bank Account No. 604320110000467

Beneficiary Name: Red Flower Publication Pvt. Ltd.

Bank & Branch Name: Bank of India, Mayur Vihar

MICR Code: 110013045

Branch Code: 6043

IFSC Code: BKID0006043 (used for RTGS and NEFT transactions)

Swift Code: BKIDINBBDOS

Send all Orders to: Subscription and Marketing Manager, **Red Flower Publication Pvt. Ltd.**, 48/41-

42, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi - 110 091(India)

Mobile: 8130750089, Phone: 91-11-79695648

E-mail: sales@rfppl.co.in, Website: www.rfppl.co.in

Instructions to Authors

Submission to the journal must comply with the Guidelines for Authors.
Non-compliant submission will be returned to the author for correction.

To access the online submission system and for the most up-to-date version of the Guide for Authors please visit:

<http://www.rfppl.co.in>

Technical problems or general questions on publishing with **IJHI** are supported by Red Flower Publication Pvt. Ltd.'s Author Support team (http://rfppl.co.in/article_submission_system.php?mid=5#)

Alternatively, please contact the Journal's Editorial Office for further assistance.

Editorial Manager

Red Flower Publication Pvt. Ltd.
48/41-42, DSIDC, Pocket-II
Mayur Vihar Phase-I
Delhi - 110 091(India)
Mobile: 9821671871, Phone: 91-11-79695648
E-mail: author@rfppl.co.in

Guidelines for Authors

Manuscripts must be prepared in accordance with "Uniform requirements for Manuscripts submitted to Biomedical Journal" developed by international committee of medical Journal Editors

Types of Manuscripts and Limits

Original articles: Up to 3000 words excluding references and abstract and up to 10 references.

Review articles: Up to 2500 words excluding references and abstract and up to 10 references.

Case reports: Up to 1000 words excluding references and abstract and up to 10 references.

Online Submission of the Manuscripts

Articles can also be submitted online from http://rfppl.co.in/customer_index.php.

1) First Page File: Prepare the title page, covering letter, acknowledgement, etc. using a word processor program. All information which can reveal your identity should be here. use text/rtf/doc/PDF files. Do not zip the files.

2) Article file: The main text of the article, beginning from Abstract till References (including tables) should be in this file. Do not include any information (such as acknowledgement, your name in page headers, etc.) in this file. Use text/rtf/doc/PDF files. Do not zip the files. Limit the file size to 400 Kb. Do not incorporate images in the file. If file size is large, graphs can be submitted as images separately without incorporating them in the article file to reduce the size of the file.

3) Images: Submit good quality color images. Each image should be less than 100 Kb in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to 400 pixels or 3 inches). All image formats (jpeg, tiff, gif, bmp, png, eps etc.) are acceptable; jpeg is most suitable.

Legends: Legends for the figures/images should be included at the end of the article file.

If the manuscript is submitted online, the contributors' form and copyright transfer form has to be submitted in original with the signatures of all the contributors within two weeks from submission. Hard copies of the images (3 sets), for articles submitted online, should be sent to the journal office at the time of submission of a revised manuscript. Editorial office: Red Flower Publication Pvt. Ltd., 48/41-42, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi - 110 091, India, Phone: 91-11-79695648, Cell: +91-9821671871. E-mail: author@rfppl.co.in. Submission page: http://rfppl.co.in/article_submission_system.php?mid=5.

Preparation of the Manuscript

The text of observational and experimental articles should be divided into sections with the headings: Introduction, Methods, Results, Discussion, References, Tables, Figures, Figure legends, and Acknowledgment. Do not make subheadings in these sections.

Title Page

The title page should carry

- 1) Type of manuscript (e.g. Original article, Review article, Case Report)
- 2) The title of the article, should be concise and informative;
- 3) Running title or short title not more than 50 characters;
- 4) The name by which each contributor is known (Last name, First name and initials of middle name), with his or her highest academic degree(s) and institutional affiliation;
- 5) The name of the department(s) and institution(s) to which the work should be attributed;
- 6) The name, address, phone numbers, facsimile numbers and e-mail address of the contributor responsible for correspondence about the manuscript; should be mentioned.
- 7) The total number of pages, total number of photographs and word counts separately for abstract and for the text (excluding the references and abstract);
- 8) Source(s) of support in the form of grants, equipment, drugs, or all of these;
- 9) Acknowledgement, if any; and
- 10) If the manuscript was presented as part at a meeting, the organization, place, and exact date on which it was read.

Abstract Page

The second page should carry the full title of the manuscript and an abstract (of no more than 150 words for case reports, brief reports and 250 words for original articles). The abstract should be structured and state the Context (Background), Aims, Settings and Design, Methods and Materials, Statistical analysis used, Results and Conclusions. Below the abstract should provide 3 to 10 keywords.

Introduction

State the background of the study and purpose of the study and summarize the rationale for the study or observation.

Methods

The methods section should include only information that was available at the time the plan or protocol for the study was written such as study approach, design, type of sample, sample size, sampling technique, setting of the study, description of data collection tools and methods; all information obtained during the conduct of the study belongs in the Results section.

Reports of randomized clinical trials should be based on the CONSORT Statement (<http://www.consort-statement.org>). When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2000 (available at http://www.wma.net/e/policy/17-c_e.html).

Results

Present your results in logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat in the text all the data in the tables or illustrations; emphasize or summarize only important observations. Extra or supplementary materials and technical details can be placed in an appendix where it will be accessible but will not interrupt the flow of the text; alternatively, it can be published only in the electronic version of the journal.

Discussion

Include summary of key findings (primary outcome measures, secondary outcome measures, results as they relate to a prior hypothesis); Strengths and limitations of the study (study question, study design, data collection, analysis and interpretation); Interpretation and implications in the context of the totality of evidence (is there a systematic review to refer to, if not, could one be reasonably done here and now?, What this study adds to the available evidence, effects on patient care and health policy, possible mechanisms)? Controversies raised by this study; and Future research directions (for this particular research collaboration, underlying mechanisms, clinical

research). Do not repeat in detail data or other material given in the Introduction or the Results section.

References

List references in alphabetical order. Each listed reference should be cited in text (not in alphabetic order), and each text citation should be listed in the References section. Identify references in text, tables, and legends by Arabic numerals in square bracket (e.g. [10]). Please refer to ICMJE Guidelines (http://www.nlm.nih.gov/bsd/uniform_requirements.html) for more examples.

Standard journal article

[1] Flink H, Tegelberg Å, Thörn M, Lagerlöf F. Effect of oral iron supplementation on unstimulated salivary flow rate: A randomized, double-blind, placebo-controlled trial. *J Oral Pathol Med* 2006; 35: 540-7.

[2] Twetman S, Axelsson S, Dahlgren H, Holm AK, Källestål C, Lagerlöf F, et al. Caries-preventive effect of fluoride toothpaste: A systematic review. *Acta Odontol Scand* 2003; 61: 347-55.

Article in supplement or special issue

[3] Fleischer W, Reimer K. Povidone iodine antiseptics. State of the art. *Dermatology* 1997; 195 Suppl 2: 3-9.

Corporate (collective) author

[4] American Academy of Periodontology. Sonic and ultrasonic scalers in periodontics. *J Periodontol* 2000; 71: 1792-801.

Unpublished article

[5] Garoushi S, Lassila LV, Tezvergil A, Vallittu PK. Static and fatigue compression test for particulate filler composite resin with fiber-reinforced composite substructure. *Dent Mater* 2006.

Personal author(s)

[6] Hosmer D, Lemeshow S. Applied logistic regression, 2nd edn. New York: Wiley-Interscience; 2000.

Chapter in book

[7] Nauntofte B, Tenovou J, Lagerlöf F. Secretion and composition of saliva. In: Fejerskov O,

Kidd EAM, editors. Dental caries: The disease and its clinical management. Oxford: Blackwell Munksgaard; 2003. p. 7-27.

No author given

[8] World Health Organization. Oral health surveys - basic methods, 4th edn. Geneva: World Health Organization; 1997.

Reference from electronic media

[9] National Statistics Online – Trends in suicide by method in England and Wales, 1979-2001. www.statistics.gov.uk/downloads/theme_health/HSQ20.pdf (accessed Jan 24, 2005): 7-18. Only verified references against the original documents should be cited. Authors are responsible for the accuracy and completeness of their references and for correct text citation. The number of reference should be kept limited to 20 in case of major communications and 10 for short communications.

More information about other reference types is available at www.nlm.nih.gov/bsd/uniform_requirements.html, but observes some minor deviations (no full stop after journal title, no issue or date after volume, etc).

Tables

Tables should be self-explanatory and should not duplicate textual material.

Tables with more than 10 columns and 25 rows are not acceptable.

Table numbers should be in Arabic numerals, consecutively in the order of their first citation in the text and supply a brief title for each.

Explain in footnotes all non-standard abbreviations that are used in each table.

For footnotes use the following symbols, in this sequence: *, †, ‡, §,

Illustrations (Figures)

Graphics files are welcome if supplied as Tiff, EPS, or PowerPoint files of minimum 1200x1600 pixel size. The minimum line weight for line art is 0.5 point for optimal printing.

When possible, please place symbol legends below the figure instead of to the side.

Original color figures can be printed in color at the editor's and publisher's discretion provided the author agrees to pay.

Type or print out legends (maximum 40 words, excluding the credit line) for illustrations using double spacing, with Arabic numerals corresponding to the illustrations.

Sending a revised manuscript

While submitting a revised manuscript, contributors are requested to include, along with single copy of the final revised manuscript, a photocopy of the revised manuscript with the changes underlined in red and copy of the comments with the point to point clarification to each comment. The manuscript number should be written on each of these documents. If the manuscript is submitted online, the contributors' form and copyright transfer form has to be submitted in original with the signatures of all the contributors within two weeks of submission. Hard copies of images should be sent to the office of the journal. There is no need to send printed manuscript for articles submitted online.

Reprints

Journal provides no free printed reprints, however a author copy is sent to the main author and additional copies are available on payment (ask to the journal office).

Copyrights

The whole of the literary matter in the journal is copyright and cannot be reproduced without the written permission.

Declaration

A declaration should be submitted stating that the manuscript represents valid work and that neither this manuscript nor one with substantially similar content under the present authorship has been published or is being considered for publication elsewhere and the authorship of this article will not be contested by any one whose name (s) is/are not listed here, and that the order of authorship as placed in the manuscript is final and accepted by the co-authors. Declarations should be signed by all the authors in the order in which they are mentioned in the original manuscript. Matters appearing in the Journal are covered by copyright but no objection will be made to their reproduction provided permission is obtained from the Editor prior to publication and due acknowledgment of the source is made.

Approval of Ethics Committee

We need the Ethics committee approval letter from an Institutional ethical committee (IEC) or an institutional review board (IRB) to publish your Research article or author should submit a statement that the study does not require ethics approval along with evidence. The evidence could either be consent from patients is available and there are no ethics issues in the paper or a letter from an IRB stating that the study in question does not require ethics approval.

Abbreviations

Standard abbreviations should be used and be spelt out when first used in the text. Abbreviations should not be used in the title or abstract.

Checklist

- Manuscript Title
- Covering letter: Signed by all contributors
- Previous publication/ presentations mentioned, Source of funding mentioned
- Conflicts of interest disclosed

Authors

- Middle name initials provided.
- Author for correspondence, with e-mail address provided.
- Number of contributors restricted as per the instructions.
- Identity not revealed in paper except title page (e.g. name of the institute in Methods, citing previous study as 'our study')

Presentation and Format

- Double spacing
- Margins 2.5 cm from all four sides
- Title page contains all the desired information. Running title provided (not more than 50 characters)
- Abstract page contains the full title of the manuscript
- Abstract provided: Structured abstract provided for an original article.
- Keywords provided (three or more)
- Introduction of 75-100 words

- Headings in title case (not ALL CAPITALS). References cited in square brackets
- References according to the journal's instructions

Language and grammar

- Uniformly American English
- Abbreviations spelt out in full for the first time. Numerals from 1 to 10 spelt out
- Numerals at the beginning of the sentence spelt out

Tables and figures

- No repetition of data in tables and graphs and in text.
- Actual numbers from which graphs drawn, provided.
- Figures necessary and of good quality (color)
- Table and figure numbers in Arabic letters (not Roman).
- Labels pasted on back of the photographs (no names written)
- Figure legends provided (not more than 40 words)
- Patients' privacy maintained, (if not permission taken)
- Credit note for borrowed figures/tables provided
- Manuscript provided on a CDROM (with double spacing)

Submitting the Manuscript

- Is the journal editor's contact information current?
- Is the cover letter included with the manuscript? Does the letter:
 1. Include the author's postal address, e-mail address, telephone number, and fax number for future correspondence?
 2. State that the manuscript is original, not previously published, and not under concurrent consideration elsewhere?
 3. Inform the journal editor of the existence of any similar published manuscripts written by the author?
 4. Mention any supplemental material you are submitting for the online version of your article. Contributors' Form (to be modified as applicable and one signed copy attached with the manuscript)

SUBSCRIPTION FORM

I want to renew/subscribe international class journal “**RFP Indian Journal of Hospital Infection**” of Red Flower Publication Pvt. Ltd.

Subscription Rates:

- Institutional: **INR 13500 / USD 1054.69**

Name and complete address (in capitals): _____

Payment detail:

Online payment link: <http://rfppl.co.in/payment.php?mid=15>

Cheque/DD: Please send the US dollar check from outside India and INR check from India made payable to ‘Red Flower Publication Private Limited’. Drawn on Delhi branch.

Wire transfer/NEFT/RTGS:

Complete Bank Account No. 604320110000467

Beneficiary Name: Red Flower Publication Pvt. Ltd.

Bank & Branch Name: Bank of India; Mayur Vihar

MICR Code: 110013045

Branch Code: 6043

IFSC Code: BKID0006043 (used for RTGS and NEFT transactions)

Swift Code: BKIDINBBDOS

Term and condition for supply of journals

1. Advance payment required by Demand Draft payable to **Red Flower Publication Pvt. Ltd.** payable at **Delhi**.
2. Cancellation not allowed except for duplicate payment.
3. Agents allowed 12.5% discount.
4. Claim must be made within six months from issue date.

Mail all orders to

Subscription and Marketing Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India)

Phone: 91-11-79695648

Cell: +91-9821671871

E-mail: sales@rfppl.co.in

RFP Indian Journal of Hospital Infection

Library Recommendation Form

If you would like to recommend this journal to your library, simply complete the form given below and return it to us. Please type or print the information clearly. We will forward a sample copy to your library, along with this recommendation card.

Please send a sample copy to:

Name of Librarian

Name of Library

Address of Library

Recommended by:

Your Name/ Title

Department

Address

Dear Librarian,

I would like to recommend that your library subscribe to the RFP Indian Journal of Hospital Infection. I believe the major future uses of the journal for your library would provide:

1. Useful information for members of my specialty.
2. An excellent research aid.
3. An invaluable student resource.

I have a personal subscription and understand and appreciate the value an institutional subscription would mean to our staff.

Should the journal you're reading right now be a part of your University or institution's library? To have a free sample sent to your librarian, simply fill out and mail this today!

Stock Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India)

Phone: 91-11-79695648

Cell: +91-9821671871

E-mail: sales@rfppl.co.in